Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...
Stocks: Real-time U.S. stock quotes reflect trades reported through Nasdaq only; comprehensive quotes and volume reflect trading in all markets and are delayed at least 15 minutes. International ...
Novo Nordisk (NVO), the company behind popular diabetes and obesity treatments Ozempic and Wegovy, saw its stock rise on Thursday after ...
Wearable and implantable biosensors that can accurately detect biological molecules in a non- or minimally invasive manner ...
Cooler February inflation doesn’t mean Fed will lower rates, promising obesity drug could challenge Novo Nordisk and Eli ...
Ignore the noise in GLP-1 stocks. Find the best value instead.
Novo Nordisk’s weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...
Novo Nordisk ( NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its ...
Novo Nordisk A/S's CagriSema faces challenges, yet new trials aim to enhance efficacy, rival Eli Lilly in obesity treatments, ...
Miguel Barclay has built a reputation on proving that good food doesn’t need to cost more than £1 a portion. Now, he’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results